Abstract: The invention discloses a compound of formula (I) wherein, at least one of R1, R2, R3 and R4 is —C(?O)Rn and R1, R2R3 and R4 are H or CH3 and Rn is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In Rn, where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds.

Abstract: This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are described herein. These compounds exhibit good hypoglycemic and 5-lipoxygenase inhibitory activities. They also inhibit tumour growth. Pharmaceutical compositions containing known adjutants and the title compounds are also within the scope of this invention.

Abstract: Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from Garcinia mangostana are rich in ?-mangostin and other demethylated xanthones. These compositions exhibit potent antioxidative activity and reduce inflammation. These compositions may be used in a method of treating TNF-?, and aP2 mediated disorders. The compositions are prepared by subjecting a hydroalcoholic extract of fruit pericarp (fruit hull) of Garcinia mangostana, wherein said hydroalcoholic extract comprises predominantly ?-mangostin, to demethylation in the presence of a Lewis acid, an organic base and a catalyst.

Abstract: A process for the production of ?-mangostin comprising the steps of preparing O-methyl ?-mangostin preferably from plants, subjecting the pure or partially pure O-methylated ?-mangostin to demethylation reaction procedure followed by purification of the said demethylated product to obtain pure ?-mangostin.

Abstract: Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.

Abstract: Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from Curcuma longa, Moringa oleifera and Murraya koenigii. The anti-adipogenic and pro-lipolytic compositions optionally contain one or more anti-obesic agents. These compositions are useful for preventing anti-inflammatory and free radical mediated diseases.

Abstract: The present invention discloses the extracts of Holoptelea integrifolia or the purified fractions isolated there from and the dietary, nutraceutical and pharmaceutical compositions comprising the same or optionally in combination with one or more known anti-obesic agents useful for the purpose of inhibition, amelioration or prevention of adipogenesis and lipolysis involved diseases. The invention further discloses a method for treating or preventing obesity and adipogenesis and lipolysis involved diseases using the compositions containing the extracts of purified fractions of Holoptelea integrifolia.

Abstract: Herbal compositions are useful for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. The herbal compositions comprise biologically effective amounts of extracts or fractions from Piper betle in combination with one or more of the extracts or fractions derived from Dolichos biflorus, Commiphora mukul, Boerhaavia diffusa, Tribulus terrestris and Zingiber officinale as active ingredients. The compositions optionally contain a bio-enhancing agent or a bio-protecting agent, along with biologically acceptable carriers or diluents. The herbal compositions may be used in a method for treating or preventing adipogenesis involved diseases in mammals.

Abstract: The invention discloses 5-lipoxygenase inhibitory product prepared from botanical sources. More specifically, the invention describes 5-lipoxygenase inhibitory extracts or bio-enriched extracts or fractions of Aphanamixis polystachya, methods of making 5-lipoxygenase inhibitory extract, and methods of treating and/or preventing disease conditions mediated by 5-lipoxygenase by using the said extract. The invention further discloses pharmaceutical or nutraceitical or dietary compositions containing therapeutically effective amounts of the extracts of Aphanamixis polystachya in combination with other known anti-inflammatory agents useful for oral, parenteral and topical administration.

Abstract: Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-?-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and antioxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-?-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.

Abstract: The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. The invention further discloses a process for the preparation of the above said triazene analogs of formula (I) and formula (II), and their pharmaceutically acceptable compositions.

Abstract: This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are: 1. R1?OCHO, R2?H, R3?COOH, R4 & R5?O 2. R1?OCOCH2Cl, R2?H, R3?COOH, R4 & R5?O 3. R1=5?-O-methylgalloyloxy, R2?H, R3?COOH, R4 & R5?O 4. R1?OCOCH2CH2COOH, R2?H, R3?COOH, R4 & R5?O 5. R1=8?,9?-Dihydro-4?-hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 6. R1=4?-Hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 7. R1=3?,4?-Dimethoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 8. R1=3?,4?-Dihydroxy-5?-methoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 9. R1?OCOCH2NH(tert-BOC), R2?H, R3?COOCH3, R4 & R5?O 10. R1?OCOCH2NH2HCl, R2?H, R3?COOH, R4 & R5?O 11. R1?OCOCH(CH3)NH2HCl, R2?H, R3?COOH, R4 & R5?O 12. R1?H, R2?OH, R3?COOCH3, R4 & R5?O 13. R1?H, R2?Br, R3?COOCH3, R4 & R5?O 14. R1?CN, R2?H, R3?COOCH3, R4 & R5?O 15. R1?SH, R2?H, R3?COOCH3, R4 & R5?O 16. R1 & R2?N(OH), R3?COOCH3, R4 & R5?O 17.

Abstract: This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are: 1. R1?OCHO, R2?H, R3?COOH, R4 & R5?O 2. R1?OCOCH2Cl, R2?H, R3?COOH, R4 & R5?O 3. R1?5?-O-methylgalloyloxy, R2?H, R3?COOH, R4 & R5?O 4. R1?OCOCH2CH2COOH, R2?H, R3?COOH, R4 & R5?O 5. R1?8?,9?-Dihydro-4?-hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 6. R1?4?-Hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 7. R1?3?,4?-Dimethoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 8. R1?3?,4?-Dihydroxy-5?-methoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 9. R1?OCOCH2NH(tert-BOC), R2?H, R3?COOCH3, R4 & R5?O 10. R1?OCOCH2NH2HCl, R2?H, R3—COOH, R4 & R5?O 11. R1?OCOCH(CH3)NH2HCl, R2?H, R3?COOH, R4 & R5?O 12. R1?H, R2?OH, R3?COOCH3, R4 & R5?O 13. R1?H, R2?Br, R3 COOCH3, R4 & R5?O 14. R1?CN, R2?H, R3?COOCH3, R4 & R5?O 15. R1?SH, R2?H, R3?COOCH3, R4& R5?O 16. R1 & R2?N(OH), R3?COOCH3, R4 & R5?O 17.

Abstract: New salts or ion pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-?-boswellic acid (AKBA) or 11-keto-?-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also be used in cosmetic or pharmaceutical composition for external treatment of body parts or organs to treat inflammatory diseases or cancer.

Abstract: This invention relates to a dietary supplement which is a phytochemical composition. This composition is capable of controlling inflammatory conditions and preventing and curing cancer in mammals. The composition comprises a synergistic mixture of standardized Boswellia extract, salts of glucosamine, and curcuminoids optionally containing bromelain, chondroitin, methylsulphonylmethane, resveratrol, extracts of white Willow and ginger, and quercetin.

Abstract: This invention describes a process for producing a fraction enriched with jujubogenin and psudojujubogenin lycosides from Bacopa species, wherein the total Bacopa saponin concentration is up to 100% when estimated by HPLC method of analysis. The present invention also describes the processes for the enrichment of new compositions and individual saponin compounds from Bacopa munnieri to more than 95% purity. It further describes an analytical HPLC method for the estimation of total Bacopa saponin fraction and its use in therapeutic applications. This invention also includes two Bacopa saponin 3-O-[?-D-glucopyranosyl-(1 3)-?-D-glucopyranosyl] jujubogenin and 3-O-[?-D-glucopyranosyl-(1 3)-?-D-glucopyranosyl] pseudojujubogenin herein referred to as bacopaside N1 of general formula (1) and bacopaside N2 of general formula (2) respectively.

Abstract: This invention relates to novel corosolic acid analogs of the formula I, wherein R1, R2, R3, R4 and R5 are as indicated below in each of said analogs: 1. R1=COCH3, R2=R3=R4=H, R5=COOH or R1, =R3=R4=H, R2=COCH3, R5=COOH 2. R1=R2=COCH3, R3=R4=H, R5=COOH 3. R1=COC5H4N, R2=R3=R4=H, R5=COOH 4. R1=COCH2NH2.HC1, R2=R3=R4=H, R5=COOH 5. R1=COCH2(CH3)NH2.HC1, R2=R3=R4=H, R5=COOH 6. R1=COCH:CHC6H2(OCH3)3, R2=R3=R4=H, R5=COOCH3 7. R1 & R2=S02, R3=R4=H, R5=COOH 8. R1=R2=R3=R4=H, R5=CONH2 9. R1=R2=R3=R4=H, R5=CONHC6H5 10. R1=R2=R3=R4=H, R5=CONHCH2CH2NH2 11. R1=R2=R3=R4=H, R5=CON(CH2CH2)2NH 12. R1=R2=R3=R4=H, R5=CONHCH2CH20H 13. R1=R2=R3=R4=H, R5=COOCH3 14. R1=R2=COCH3, R3=R4=H, R5=COOCH3 15. R1=R2=H, R3 & R4=0, R5=COOCH3 16. R1=R2=COCH3, R3 & R4=0, R5=COOCH3 17. R1=R2=H, R3 & R4=0, R5=COOH 18. R1=R2=COCH3, R3 & R4=0, R5=COOH 19. R1 & R2=S02, R3 & R4=0, R5=COOH 20. R1=R2=H, R3 & R4=0, R5=CONH2 21. R1=R2=R3=H, R4=OH, R5=CONH2 22. R1=R2=R3=H, R4=OH, R5=COOCH3 23. R1=R2=R3=R4=H, R5=CH20H 24.

Abstract: This invention relates to novel AKBA analogs of the formula I given below: Where in R1, R2, R3, R4 and R5 in each of the said analogs are:— 1. R1?OCHO, R2?H, R3?COOH, R4 & R5?O 2. R1?OCOCH2Cl, R2?H, R3?COOH, R4 & R5?O 3. R1=5?-O-methylgalloyloxy, R2?H, R3?COOH, R4 & R5?O 4. R1?OCOCH2CH2COOH, R2?H, R3?COOH, R4 & R5?O 5. R1=8?,9?-Dihydro-4?-hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 6. R1=4?-Hydroxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 7. R1=3?,4?-Dimethoxycinnamoyloxy, R2?H, R3?COOH, R4 & R5?O 8. R1=3?,4?-Dihydroxy-5?-methoxycinnamoyloxy, R2?H, R3 COOH, R4 & R5?O 9. R1?OCOCH2NH(tert-BOC), R2?H, R3?COOCH3, R4 & R5?O 10. R1?OCOCH2NH2HCl, R2?H, R3—COOH, R4 & R5?O 11. R1?OCOCH(CH3)NH2HCl, R2?H, R3?COOH, R4 & R5?O 12. R1?H, R2?OH, R3?COOCH3, R4 & R5?O 13. R1?H, R2?Br, R3 COOCH3, R4 & R5?O 14. R1?CN, R2?H, R3?COOCH3, R4 & R5?O 15. R1?SH, R2?H, R3?COOCH3, R4& R5?O 16. R1 & R2?N(OH), R3?COOCH3, R4 & R5?O 17.

Abstract: This invention relates to a dietary supplement which is a phytochemical composition. This composition is capable of controlling inflammatory conditions and preventing and curing cancer in mammals. The composition comprises a synergistic mixture of standardized Boswellia extract, salts of glucosamine, and curcuminoids optionally containing bromelain, chondroitin, methylsulphonylmethane, resveratrol, extracts of white Willow and ginger, and quercetin.

Abstract: The invention relates to a process for producing a fraction enriched upto 100% of 3-O-acetyl-11-keto-&bgr;-boswellic acid. An organic solvent extract of gum resin from Boswellia species is first subjected to oxidation and then acetylation or vice versa. This converts the less potent boswellic acids present in the fraction to AKBA. This treated fraction is subjected to further purification and separation by chromatographic separation techniques to enhance its purity and to remove contaminants therefrom. This process provide an access to a fraction enriched in 10-100% AKBA for therapeutic applications.